ABT vs ACGL Stock Comparison

Scores Breakdown

Metric	ABT	ACGL
📈 Growth	22/30	14/30
💰 Profitability	17/20	16/20
🏦 Financial Health	15/20	19/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	3/10
Overall Score	72/100	68/100

Side-by-Side Summaries

ABT Analysis	ACGL Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Across the 8 most recent quarters (Q1 2026 through Q2 2024), ARCH Capital's revenues edged from about $4.521B to $4.229B, a decline of roughly 6-7%. Net income moved from about $1.047B to $0.988B, a modest downshift. The trajectory shows quarterly fluctuations but an overall stable earnings base, with operating income around $1.1B+ in most periods. 💰 Margins & Cash Flow Margins hovered in the mid-20% range (roughly 21–26%), and operating margins were similar, signaling disciplined costs and underwriting leverage. Cash flow: operating cash flow was robust in most quarters (e.g., Q1 2026 continuing ops of $1.189B; Q4 2025 around $1.404B), while investing and financing activities were frequently negative, reflecting asset deployment and capital returns. In Q1 2026, net cash flow was -$0.286B due to financing outflows. 🛡️ Balance Sheet & Liquidity Assets around $81.4B in Q1 2026, with current liabilities around $57.3B; current ratio ~1.4x. Equity near $24.2B and noncurrent liabilities essentially zero, implying strong liquidity and flexibility. ⚠️ Key Drivers & Risks Drivers: Underwriting strength and capital management; steady demand for risk transfer. Risks: Catastrophe exposure and rate sensitivity; interest-rate and valuation sensitivity.

ABT Analysis

ACGL Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Across the 8 most recent quarters (Q1 2026 through Q2 2024), ARCH Capital's revenues edged from about $4.521B to $4.229B, a decline of roughly 6-7%. Net income moved from about $1.047B to $0.988B, a modest downshift. The trajectory shows quarterly fluctuations but an overall stable earnings base, with operating income around $1.1B+ in most periods.

💰 Margins & Cash Flow

Margins hovered in the mid-20% range (roughly 21–26%), and operating margins were similar, signaling disciplined costs and underwriting leverage. Cash flow: operating cash flow was robust in most quarters (e.g., Q1 2026 continuing ops of $1.189B; Q4 2025 around $1.404B), while investing and financing activities were frequently negative, reflecting asset deployment and capital returns. In Q1 2026, net cash flow was -$0.286B due to financing outflows.

🛡️ Balance Sheet & Liquidity

Assets around $81.4B in Q1 2026, with current liabilities around $57.3B; current ratio ~1.4x. Equity near $24.2B and noncurrent liabilities essentially zero, implying strong liquidity and flexibility.

⚠️ Key Drivers & Risks

Drivers: Underwriting strength and capital management; steady demand for risk transfer.
Risks: Catastrophe exposure and rate sensitivity; interest-rate and valuation sensitivity.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"